Mesoblast limited
(ASX:MSB) has been granted three new patents by the United States Patent and Trade Mark Office (USPTO) and the State Intellectual Property Office of China.
The USPTO patent extends Mesoblast’s exclusive commercial rights in the US by more than seven years for its current products.
Two separate Chinese patents provide product commercial rights of protection through to 2025 for an unlimited range of the company’s Mesenchymal Precursor Cell (MPC) based products.
Mesoblast says the Chinese patents underpin its corporate strategy to target the world’s largest emerging market for regenerative medicines.
Mesoblast reported a $71.1 million loss in the 2012 financial year.
